Denovo Biopharma
Denovo Biopharma is a privately-held US biotech company seeking to provide a novel biomarker solution to personalize drug development.
Its work includes re-evaluating medicines that have failed in general patient populations and studying them in the original indication in biomarker-selected sub-populations.
In April 2017 Denovo obtained an exclusive license to liafensine (DB104), a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI), a late-stage CNS drug, from contract research and manufacturing organization Albany Molecular Research.
Latest Denovo Biopharma News & Features
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze